Vaccine Stocks: Another Pandemic Spike May be Ahead

0
661

The pandemic is getting out of hand.

At the moment, about 160,000 Americans are testing positive for CV-19 every day – an increase of about 14% over the last two. Week.  “A small handful of hotspots, including Florida, Louisiana and Missouri, have begun to improve over the past two weeks, although cases are still rising in 44 states,” says Axios.

“Hospital capacity still remains dangerously strained in some parts of the country. Five Southeastern states — Alabama, Georgia, Texas, Florida and Arkansas — are still using over 90% of their ICU beds,” they added.

Now, according to former US FDA Chief Scott Gottlieb, the Northeast could experience another jump in cases tied to the delta variant.  “I think our true delta wave is going to start to build after Labor Day here in the Northeast and the northern part of the country,” added Gottlieb, as quoted by CNBC.

If that’s the case, vaccine stocks could ramp even higher.

Look at Moderna, for example.

The company just initiated its submission process for US FDA approval of its CV-19 booster shot. According to Barron’s, “The company said the submitted data showed that the booster dose at the 50 ug dose level induced ‘robust antibody responses against the Delta variant.’ Moderna expects to submit data to the European Medicines Agency and other regulators.”

The US FDA also gave full approval to Pfizer and BioNTech for their vaccines, too.

In fact, on August 23:

“Tthe U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.”

Hopefully, we’re nearing an end to the pandemic.  Should it persist, these are three of the top vaccine stocks to consider.

LEAVE A REPLY

Please enter your comment!
Please enter your name here